AIDS Treatment News - 1995

• AIDS Treatment News - 1995
• Issue #214
• Women and AIDS -- Unexplained Higher Risk of Death
• FDA Advisory Committees Meet January 26 on Salk HIV-1 Immunogen
• Oral Ganciclovir Approved
• AIDS-Related Research Meetings, January and February 1995
• 1995: Politics
• 1995: Business
• Some Vitamins Associated with Decreased Risk of AIDS and Death


• Issue #215
• New Information on HIV Rapid Turnover - What Does It Mean?
• Kaposi's Sarcoma: Possible Foscarnet Treatment?
• 1995 Outlook: Research Strategy
• Protease Inhibitor Task Force: Opportunity for Participation
• FDA Advisory Committees: Hotline for Upcoming Meetings
• International Conference for People Living with HIV and AIDS, Cape Town, South Africa, March 6-10; Pre- Conference for Wo
• KS, DOX-SL: FDA Hearing February 14


• Issue #216
• Human Retroviruses and Related Infections -- Major U.S. Scientific AIDS Conference of 1995. Part I
• Action Alert: Balanced Budget Amendment
• Patent Office Expedites AIDS, Cancer Inventions
• San Francisco: Self-Empowerment in HIV Disease Symposium, Mar. 4
• San Francisco Area: Computerized Search for Local Clinical Trials
• AIDS, Cancer Patent Priority: Interview with Commissioner Bruce Lehman


• Issue #217
• Valacyclovir Study Stopped -- Worse Survival
• AZT: Pediatric Study Changed After Worse Monotherapy Survival
• Basic Science and Clinical Trials: Interview with William Paul, Director of the Office of AIDS Research
• Kaposi's Sarcoma: DOX-SL Approval Recommended
• AIDS Clinical Trials: Why They Have Recruiting Problems


• Issue #218
• IL-2: U.S. National Institutes of Health Study Published
• Proving Clinical Benefit in Small, Rapid Trials: Statement to National Task Force on AIDS Drug Development
• Immune Restoration -- Conference Outlines Future Directions
• Sulfasalazine: Arthritis Drug Increases CD4 Count?
• Viatical Settlement Tax Reform: Republicans Support Relief, Democrats Divided
• Research Meetings, March 1995


• Issue #219
• Protease Inhibitors and Beyond: Interview with David Feigal, M.D.
• Protease Inhibitors: Merck Plans Larger Trials, Expanded Access
• ICC Trials -- First Study Enrolling
• Protease Inhibitor Consensus Statement
• Mothers March Against AIDS, May 7; Congressional Visits May 8


• Issue #220
• Merck Protease Inhibitor MK-639 -- Trial Cities Announced
• Infected Infant Appears to Clear HIV
• 3TC and Protease Inhibitors: Citizen's Petition Asks Faster Approval
• Topotecan Now Available for HIV, PML Research
• 3TC: Expanded Access Will Be Limited
• FDA Reform in Congress: AIDS Community Absent
• National AIDS Treatment Information Project
• ICC Trials -- Enrollment Problem
• Proposal: Monitoring Program for Early Rapid Testing of New AIDS Treatments


• Issue #221
• International AIDS Candlelight Memorial, Sunday May 21, in 250 Cities in 47 Nations
• Congress: How to Help
• New York City: Anabolics, Wasting Symposium, May 17
• Thalidomide and HIV: Several Possible Uses
• Nerve Growth Factor: Major Trial Canceled, Revived After Protest
• Proposal: Small Trials for Screening Antiviral Combinations
• Merck Protease Inhibitor: New International Contact Numbers
• Viral Load Success: Call for Information


• Issue #222
• Stanford Researchers Find Loss of "Naive" T-Cells
• 3TC Expanded Access Program: New Requirement for CD4 Less Than 100
• AIDS Research Meetings, May 1995 and Later
• Agouron Protease Inhibitor AG1343: Activity Reported
• D4T: New Clinical Data Confirms Benefit
• ICC Trials: New Option on Laboratory Tests


• Issue #223
• New Trial Proposed for When Drugs Fail
• Antiviral Conference Reports
• California: New Drugs Added to AIDS Drug Assistance Program
• Religious Coalition Opposes Gene Patents
• Abbott: Major Protest over Lack of Access


• Issue #224
• Chinese Medicine: Where Does It Work Best in HIV/AIDS?
• Gallo Starts Major AIDS Research Institute in Baltimore
• Diarrhea, and the Experimental Treatment Saccharomyces boulardii
• Lymphoma: New TAG Report
• When Treatments Go Untried


• Issue #225
• Viral Load Predicts AIDS Progression
• Viral Load Reimbursement Information from Chiron Reimbursement Service
• Bioelectrical Impedance Analysis (BIA) May Predict AIDS Survival
• PI PERSPECTIVE May 1995 Now Available from Project Inform
• HIV Pathogenesis: Teleconference June 29 in Twelve Cities
• Merck Protease Inhibitor Trial Seeks Persons with CD4 Count Under 50
• Internet: Pain Management Information on World Wide Web
• New York: AIDS Research Teach-In, June 24
• San Francisco: Medical Marijuana on Viacom Cable, June 20
• San Francisco: Sinusitis Study of Traditional Chinese Medicine
• California Residents: Medi-Cal May Pay Your Private Health Insurance Premiums
• Federal Employees: Insurance Open Season
• AIDSWatch '95 on Capitol Hill
• World Bank in AIDS Prevention Controversy
• "UN50" Demonstration June 25 in San Francisco


• Issue #226
• Wasting Syndrome -- Affordable Treatments
• Combination Antiretroviral Treatment: New Views, Evolving Practices
• Combination Treatment and Single Drugs: Interview with Margaret Poscher, M. D.
• NAC Users: You Can Help NAC Research
• Protease Inhibitor: Roche Lottery Deadline July 21
• Animal Cell Transplantation: FDA Meeting July 13 and 14


• Issue #227
• AIDS Research "Spin-off" -- Ganciclovir CMV Prevention After Liver Transplantation
• NAPWA Opens Pharmacy
• Exon Amendment: Threat to AIDS Prevention and Activism?
• Cryptosporidium in Water: CDC Guidelines on How to Protect Yourself
• Merck Protease Inhibitor Available to Persons with CD4 Count 50 or Less -- Must Register by August 11
• Combination Treatment and Single Drugs: Interview with Margaret Poscher, M.D. (Part II of II)


• Issue #228
• California: Medi-Cal Can Pay for Human Growth Hormone for Some Patients
• FDA Reform: Activists' Proposals
• Comment: Workable Clinical Trials [or, AIDS "Confirmatory" Trials: What's Wrong, and How to Move Forward Today]
• FDA Workshop on Clinical Trial Design, September 6-7 -- Registration by Aug. 18
• New Antiretroviral Strategies: Interview with Marcus Conant, M.D.
• Boston: Important Trial of Treatment Vaccine, CD4 > 500
• 3TC: Now Available Again Up To CD4 of 300


• Issue #229
• ICAAC Conference, September 17-20, in San Francisco
• FDA Warning on Raw Oysters
• Alternative Medicine and HIV/AIDS: Request for Applications
• Is NIH AIDS Research in Danger?
• "Confirmatory" Trials: Symptom Reduction As Efficacy Measure
• San Francisco: AIDS TREATMENT NEWS Needs Office Space
• House Moves to Block Internet Censorship
• Merck Protease Inhibitor Note: Expanded Access Program Registrants Should Receive, and Return, Mailed Confirmation


• Issue #230
• Acupuncture and Chinese Medicine; Interview with Tom Sinclair, L. Ac.
• Hydroxyurea and ddI: French Study Published
• Thalidomide: New Expanded Access for Wasting
• d4T Dose Clarification
• San Francisco: Viral Load Trial Offers Free Tests
• National AIDS Treatment Advocates Forum, October 15-18, Los Angeles
• National Skills Building Conference, October 19-22, Los Angeles
• Surrogate Markers Meeting, October 16-18, McLean, Virginia
• Next AIDS TREATMENT NEWS Delayed One Week
• Health Insurance: Widespread Copayment Abuse


• Issue #231
• Agouron Protease Inhibitor
• Medicaid in Congress: Serious Threat to Health Care
• Symptom-Reduction Trials at FDA Clinical Trials Workshop
• Major Study Shows AZT Monotherapy Inferior
• ICAAC 1995: New Perspectives on Treatment
• Saquinavir -- New Lottery
• Drug Policy Reform: Ninth International Conference, October 18-21
• Boston, Galveston, Jackson County, Jefferson County, New York City, Portland -- New Saquinavir Trial
• San Francisco: Virology/Immunology Meeting, October 12-13
• San Francisco: Nutrition and Wasting Seminar, October 11
• Saquinavir (Roche Protease Inhibitor) At Higher Doses
• Abbott Protease Inhibitor In Combination: Sustained Viral Load Drop
• Ritonavir, Saquinavir Combination -- & Warning


• Issue #232
• Protease Inhibitors and Prevention of Cross Resistance
• AZT Delta Study: Major European/Australian Study Finds Combinations Better Than AZT Alone
• Los Angeles, New York, Stanford University: HBY 097, New Drug May Weaken HIV
• California: Marijuana Compassionate Use Statewide Initiative
• New York, Ohio, Ontario: Health Promotion Workshops
• Vaccine Research Meeting, Oct. 16, Near Washington
• ICAAC's Small Advances
• AIDS Information Obstacles


• Issue #233
• Viral Load: New "Strategy" Trial in 15 U.S. Cities
• Guidelines for Clinical Management Using Plasma HIV RNA Quantitation
• White House Meeting on AIDS
• FDA Antiviral Advisory Hearings on Lamivudine (Epivir(TM), 3TC), Saquinavir (Invirase(TM)), Stavudine (Zerit(TM), d4T), N
• International Conference, Vancouver 1996: Arrangements, Deadlines
• Thalidomide Conflict -- How to Help
• Internet Newsgroup sci.med.aids -- New Addresses
• California: Governor Vetoes Cryptosporidium Bill
• San Francisco Area: Testosterone Replacement Study, Injection vs. Patch
• Women Prisoners: San Francisco Bay Area Events
• Office of AIDS Research Announces Advisory Council


• Issue #234
• Project Inform's THE HIV DRUG BOOK Now Available
• Thalidomide for Wasting Syndrome: Progress Toward Compromise
• NIH Research Evaluation: Last Meeting on Clinical Trials November 13, Public Comment Allowed
• NIH Role in Clinical Research
• CMV: Oral Ganciclovir for Prevention
• CMV: New Screening Program
• Cryptosporidiosis Information Phone/Fax Line
• Protease Inhibitor Trial Drops AZT-Only Arm
• Help Wanted: AIDS Treatment Activist, Atlanta
• Peptide T: Negative Trial Result


• Issue #235
• New AIDS Treatment Article Series Available
• U.S./China AIDS Research Proposed
• Protease Inhibitors: Drug Resistance and Cross Resistance Overview
• Grapefruit Juice and Saquinavir
• Vancouver Conference Internet Address
• FDA Reform: New Senate Bill


• Issue #236
• Lamivudine (3TC) Approved for Combination Use with AZT
• PMPA in Perspective
• DOXIL Approved for KS
• DOXIL Available in Government Trial
• New Double Vs. Triple Antiviral Combination Study, CD4 200-500, No Prior Treatment
• Identical Twins Needed to Donate Blood
• Medical Marijuana: 80% U.S. Voter Support
• California: Medical Marijuana Petition Drive Begins
• Internet Censorship: Congress Moves Toward Final Decision


• Issue #237
• Saquinavir (Invirase): First Protease Inhibitor Approved -- Reimbursement, Information Hotline Numbers
• Abbott Protease Inhibitor Lottery in January, CD4 Under 50 -- Registration Now
• Abbott Protease Inhibitor: Early Results Reported
• Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive
• Wasting Syndrome: Oral Oxandrolone Re-Released in U.S.
• Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease
• Human Retroviruses, Immune-Based, and CPCRA Meetings, Washington D.C. Late January
• ACTG Clinical Trial Sites: Seven Cut, Two Added
• New York: Protease Inhibitor Forum, January 6
• Computer Censorship: Effect on AIDS TREATMENT NEWS
• AIDS TREATMENT NEWS Selected Index

All information on AIDS.ORG is designed to support, but not replace your relationship with your doctor, and is intended soley for educational or research purposes. Any and all personal information you may provide us with is never released to anyone at any time. Your privacy and trust is extremely important to us.

• News
• Topics
• Experience
• Donate
• About Us

• Headlines
• AIDS Treatment News